Seeing Is Believing
Currently out of the existing stock ratings of Gil Blum, 243 are a BUY (98.78%), 3 are a HOLD (1.22%).
Analyst Gil Blum, currently employed at NEEDHAM, carries an average stock price target met ratio of 24.79% that have a potential upside of 48.51% achieved within 116 days. Previously, Gil Blum worked at TRUIST.
Gil Blum’s has documented 464 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NRIX, Nurix Therapeutics at 12-Jul-2024.
Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 10/31/2023. The price target of $82 was fulfilled within 7 days with a profit of $14.69 (21.82%) receiving and performance score of 31.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
2
$0.6 (42.86%)
7 months 8 days ago
0/2 (0%)
$0.7 (53.85%)
Buy
2
$0.6 (42.86%)
36
1 years 13 days ago
0/2 (0%)
$0.59 (41.84%)
Hold
2
$0.6 (42.86%)
2
1 years 14 days ago
1/3 (33.33%)
$0.57 (39.86%)
7
Buy
1 years 7 months 19 days ago
0/2 (0%)
$13.44 (140.59%)
Buy
2 years 2 months 9 days ago
0/1 (0%)
$19.05 (212.85%)
Which stock is Gil Blum is most bullish on?
Which stock is Gil Blum is most reserved on?
What Year was the first public recommendation made by Gil Blum?